bimekizumab
ucb pharmaceuticals
['bimekizumab', 'be-mobile']
ab0411 #acr22 bimekizumab in as
p3 24 wk pbo control study be-mobile 2 221 bkz, 111 pbo
wk 16 asas40: bkz 45%, 22% pbo p&lt;0.001
efficacy in both tnf naive and tnf failure pts
wk 24: 1/2 pts has asdas&lt;2.1
nasopharyngitis (6%), diarrhea (4%), h/a (3.6%) candidiasis (3%) 
Rheumatologist at Institute for Rheumatic and Autoimmune Disease at Overlook Hospital, proud Hopkins alum, health care advocate, Eagles fan entering Giants land